indomethacin has been researched along with Retrolental Fibroplasia in 21 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prophylactic administration of indomethacin reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage in very-low-birth-weight infants (those with birth weights below 1500 g)." | 5.09 | Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. ( Davis, P; Moddemann, D; Ohlsson, A; Roberts, RS; Saigal, S; Schmidt, B; Solimano, A; Vincer, M; Wright, LL, 2001) |
| " These factors (immaturity, hyperoxia, hypoxia, blood transfusions, intraventricular hemorrhage, apnea, infection, hypercarbia, hypocarbia, patent ductus arteriosus, prostaglandin synthetase inhibitors, vitamin E deficiency, lactic acidosis, prenatal complications, genetic factors) may all be present in an infant." | 4.76 | A reexamination of the role of oxygen in retrolental fibroplasia. ( Dangman, B; Lucey, JF, 1984) |
| " Infants who had PDA and survived beyond 72 hours were included in multivariable logistic regression analyses that compared mortality or any severe neonatal morbidity (intraventricular hemorrhage grades ≥ 3, retinopathy of prematurity stages ≥ 3, bronchopulmonary dysplasia, or necrotizing enterocolitis stages ≥ 2) between treatment groups (conservative management, indomethacin only, surgical ligation only, or both indomethacin and ligation)." | 3.78 | Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. ( Allen, AC; Aziz, K; Lee, SK; Mirea, L; Ohlsson, A; Sankaran, K; Seshia, M; Shah, PS, 2012) |
| "Increasing indomethacin concentrations above the levels achieved with a conventional dosing regimen had little effect on the rate of PDA closure but was associated with higher rates of moderate/severe ROP and renal compromise." | 2.73 | Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. ( Buchh, B; Chorne, N; Clyman, R; Ewig, A; Fields, S; Ianus, V; Jegatheesan, P; Lin, E; Milstein, J; Moon-Grady, A; Padbury, J; Schreiber, M; Tacy, T; Yoon, G, 2008) |
| "Indomethacin was administered along with the oxygen exposure as a single subcutaneous dose of 0." | 1.30 | Indomethacin improves oxygen-induced retinopathy in the mouse. ( Higgins, RD; Nandgaonkar, BN; Rotschild, T; Yu, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| AlRyalat, SA | 1 |
| Al Oweidat, K | 1 |
| Al-Amer, A | 1 |
| Khader, A | 1 |
| Ajaj, A | 1 |
| Alessa, Z | 1 |
| Roto, A | 1 |
| Jegatheesan, P | 1 |
| Ianus, V | 1 |
| Buchh, B | 1 |
| Yoon, G | 1 |
| Chorne, N | 1 |
| Ewig, A | 1 |
| Lin, E | 1 |
| Fields, S | 1 |
| Moon-Grady, A | 1 |
| Tacy, T | 1 |
| Milstein, J | 1 |
| Schreiber, M | 1 |
| Padbury, J | 1 |
| Clyman, R | 1 |
| Hammerman, C | 1 |
| Darlow, BA | 1 |
| Saldeño, YP | 1 |
| Favareto, V | 1 |
| Mirpuri, J | 1 |
| Mirea, L | 1 |
| Sankaran, K | 1 |
| Seshia, M | 1 |
| Ohlsson, A | 2 |
| Allen, AC | 1 |
| Aziz, K | 1 |
| Lee, SK | 1 |
| Shah, PS | 1 |
| Schmidt, B | 3 |
| Asztalos, EV | 1 |
| Roberts, RS | 2 |
| Robertson, CM | 1 |
| Sauve, RS | 1 |
| Whitfield, MF | 1 |
| Al-Amro, SA | 1 |
| Al-Kharfi, TM | 1 |
| Thabit, AA | 1 |
| Al-Mofada, SM | 1 |
| Yeh, TF | 1 |
| Raval, D | 1 |
| Pyati, S | 1 |
| Pildes, RS | 1 |
| Peckham, GJ | 1 |
| Miettinen, OS | 1 |
| Ellison, RC | 1 |
| Kraybill, EN | 1 |
| Gersony, WM | 1 |
| Zierler, S | 1 |
| Nadas, AS | 1 |
| Lucey, JF | 1 |
| Dangman, B | 1 |
| Flower, RW | 1 |
| Bolling, J | 1 |
| Feman, SS | 1 |
| Mellander, M | 1 |
| Cotton, R | 1 |
| Doray, BH | 1 |
| Orquin, J | 1 |
| Nandgaonkar, BN | 1 |
| Rotschild, T | 1 |
| Yu, K | 1 |
| Higgins, RD | 1 |
| Davis, P | 1 |
| Moddemann, D | 1 |
| Saigal, S | 1 |
| Solimano, A | 1 |
| Vincer, M | 1 |
| Wright, LL | 1 |
| Harrold, J | 1 |
| Schrager, GO | 1 |
| Stiris, T | 1 |
| Suguihara, C | 1 |
| Hehre, D | 1 |
| Goldberg, RN | 1 |
| Flynn, J | 1 |
| Bancalari, E | 1 |
| Flynn, JT | 1 |
| Cassady, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)[NCT00009646] | Phase 3 | 1,202 participants (Actual) | Interventional | 1993-11-30 | Completed | ||
| Lactoferrin Infant Feeding Trial - LIFT_Canada[NCT03367013] | Phase 3 | 453 participants (Actual) | Interventional | 2018-02-16 | Active, not recruiting | ||
| Enteral Supplementation With High-dose Docosahexaenoic Acid on the Risk for Bronchopulmonary Dysplasia in Very Preterm Infants: A Collaborative Study Protocol for an Individual Participant Data Meta-analysis[NCT05915806] | 1,801 participants (Actual) | Interventional | 2023-07-30 | Active, not recruiting | |||
| Clinical Research on the Predictive Effect of Neonatal Morbidities on the Poor Outcomes to Very Low Birth-weight and Extremely Low Birth-weight Infants[NCT03104946] | 834 participants (Actual) | Observational | 2013-09-01 | Completed | |||
| High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study[NCT00589953] | Phase 2 | 22 participants (Actual) | Interventional | 2007-07-31 | Terminated | ||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for indomethacin and Retrolental Fibroplasia
| Article | Year |
|---|---|
A reexamination of the role of oxygen in retrolental fibroplasia.
Topics: Anencephaly; Apnea; Carbon Dioxide; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Exchange Transfu | 1984 |
Evidence-based neonatology: making a difference beyond discharge from the neonatal nursery.
Topics: Breast Feeding; Cryotherapy; Cyclooxygenase Inhibitors; Evidence-Based Medicine; Extracorporeal Memb | 2002 |
Retrolental fibroplasia: update.
Topics: Anemia; Blood Vessels; Carbon Dioxide; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Mal | 1986 |
5 trials available for indomethacin and Retrolental Fibroplasia
| Article | Year |
|---|---|
Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial.
Topics: Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiogr | 2008 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA).
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, | 1983 |
Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin.
Topics: Bronchopulmonary Dysplasia; Child Development; Clinical Trials as Topic; Combined Modality Therapy; | 1984 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
13 other studies available for indomethacin and Retrolental Fibroplasia
| Article | Year |
|---|---|
Perinatal events predicting retinopathy of prematurity in extremely pre-term infants.
Topics: Birth Weight; Cardiovascular Agents; Cellulitis; Cerebrospinal Fluid Shunts; Continuous Positive Air | 2020 |
Indomethacin and retinopathy of prematurity: the hidden paradox.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Retinopathy of Prematurity; Vasoco | 2008 |
Indomethacin and retinopathy of prematurity.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Ductus Arteriosus, P | 2009 |
Prolonged persistent patent ductus arteriosus: potential perdurable anomalies in premature infants.
Topics: Analysis of Variance; Bronchopulmonary Dysplasia; Cardiac Surgical Procedures; Case-Control Studies; | 2012 |
Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Ductus Arte | 2012 |
Risk factors for acute retinopathy of prematurity.
Topics: Birth Weight; Cerebral Hemorrhage; Female; Gestational Age; Humans; Incidence; Indomethacin; Infant, | 2007 |
Indomethacin and retrolental fibroplasia.
Topics: Humans; Indomethacin; Infant, Newborn; Infant, Premature; Retinopathy of Prematurity | 1984 |
The influence of indomethacin on retinopathy of prematurity.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Retinopathy of Prematurity | 1983 |
[Retinopathy in premature infants].
Topics: Animals; Dogs; Humans; Indomethacin; Infant; Male; Oxygen Inhalation Therapy; Retinopathy of Prematu | 1982 |
Indomethacin improves oxygen-induced retinopathy in the mouse.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Indomethacin; Infant, Newborn; Injections, | 1999 |
PDAs, prostaglandins, and RLF.
Topics: Aspirin; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Pregnancy; Prosta | 1978 |
Effect of cyclooxygenase inhibition on retinal and choroidal blood flow during hypercarbia in newborn piglets.
Topics: Animals; Animals, Newborn; Arachidonic Acids; Carbon Dioxide; Choroid; Humans; Indomethacin; Infant, | 1992 |
Relation between persistent patency of the ductus arteriosus and retinopathy of prematurity.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant | 1988 |